The association between early childhood serum 25-hydroxyvitamin D (25(OH)D) and eosinophilic asthma remains unclear. We ...

The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with ...

Current treatments focus on eosinophilic asthma, neglecting non-eosinophilic types. Developments in biologic therapies for ...

Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.

North America severe asthma market is set for growth, driven by high asthma prevalence, increased awareness, and advanced treatment options for severe cases. Ankush Nikam Future Market Insights, Inc.

Among adults with severe eosinophilic asthma and previous biologic use, benralizumab for 48 weeks aided in reducing exacerbations and improving asthma symptom control, according to results ...

AD-17002 is under clinical development by Advagene Biopharma and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

Blackline Safety Corp. , a global leader in connected safety technology, together with Total Safety, a leading global provider of integrated industrial safety solutions, today announced a new $1.6 ...

BD (Becton, Dickinson and Company) , a leading global medical technology company, today announced the results of a new survey, revealing that 72% of women in the United States have delayed having a ...

The study highlights T2-low and T17-high asthma endotypes in minoritized youths, offering insights for precision medicine and ...

A noninvasive approach could help clinicians prescribe medications more precisely for patients according to endotype.